ASM International N.V. reports third quarter 2023
Almere, The Netherlands
October 24, 2023, 6 p.m. CET
ASM International N.V. (Euronext Amsterdam: ASM) today reports its third quarter 2023 operating results (unaudited).
Robust results and orders amidst continued soft market conditions
|€ million||Q3 2022||Q2 2023||Q3 2023|
|YoY change % at constant currencies||1%||(48%)||0%|
|YoY change % at constant currencies||33%||21%||9%|
|Normalized gross profit margin 1)||48.1%||49.0%||48.9%|
|Normalized operating result 1)||160.3||180.1||157.2|
|Normalized operating result margin 1)||26.3%||26.9%||25.3%|
|Share in income of investments in associates (excluding amortization intangible assets resulting from the sale of ASMPT stake 2013)||19.6||9.2||0.4|
|Amortization intangible assets (resulting from the sale of ASMPT stake in 2013)||(3.6)||(0.2)||(0.1)|
|Impairment of investments in associates||(321.4)||0.0||0.0|
|Normalized net earnings 2)||174.9||160.7||139.1|
1 Excluding amortization of fair value adjustments from purchase price allocations (before tax)
2 Excluding amortization of fair value adjustments from purchase price allocations (net of tax), change in fair value of the contingent consideration (LPE earn-out) and impairment of ASMPT
- New orders of €627 million for the third quarter 2023 were about flat at constant currencies compared to the same period last year (decreased by 7% as reported).
- Year-on-year revenue growth for the third quarter 2023 was 9% at constant currencies (2% as reported).
- Normalized gross profit margin of 48.9%, improved compared to 48.1% in the same quarter last year, mainly explained by mix, including a continued solid contribution from China sales.
- Normalized operating result for the third quarter 2023, slightly decreased from €160 million last year to €157 million this year, with slightly higher sales and a higher normalized gross profit margin offset by increased R&D expenses.
- Normalized net earnings for the third quarter 2023 were €139 million, down from €175 million in Q3 last year, and included a translation gain of €3 million compared to a translation gain of €25 million in Q3 2022 and a translation gain of €8 million in Q2 2023.
- Net earnings included a negative impact of €10 million (net of tax) relating to PPA expenses. Details of (estimated) amortization and earn-out expenses (PPA expenses) relating to the 2022 acquisitions of LPE and Reno are found in Annex 2.
“ASM delivered robust results amidst continued soft market conditions,” said Benjamin Loh, President and CEO of ASM. “Revenue increased 9% at constant currencies compared to prior year to €622 million, which is at the top end of our previous guidance of €580-620 million. The gross margin was again relatively strong at around 49% in Q3, with a positive mix including again significantly higher contribution from the Chinese market. Slightly higher revenue and gross margin was offset by further increases in R&D investments resulting in an operating margin of 25.3% in Q3. For FY 2023 we expect an operating margin of at least 26%, somewhat better than the previous forecast of 26% or slightly lower.
Orders came in at €627 million in Q3, about flat compared to last year (at constant currencies), and up compared to the lower level in Q2 2023, despite the generally weaker market conditions. Against the backdrop of continued economic pressure and geopolitical tensions, large parts of the semiconductor end markets are still sluggish and the timing and strength of recovery is still uncertain. As a consequence, demand from our customers in the leading-edge logic/foundry segment remains relatively soft, and this also includes the earlier reported push outs due to delays in fab readiness. On the positive side, leading logic/foundry customers remain committed to transition to the next node which will be based on gate-all-around (GAA) technology. As previously communicated, we expect the first meaningful GAA orders in Q4 2023, of which part has now already been booked in Q3. Despite some advanced-technology investments in the DRAM segment, overall demand in memory is still low and not expected to recover in the near term. The power/analog market so far held up well but is now also showing signs of slowdown, including in the automotive and industrial segments. Traction in SiC Epi remains solid and we still expect revenues in excess of €130 million for this business this year.
An important event during the quarter was our Investor Day 2023. Despite the current market weakness, we increased our revenue target for 2025 to €3.0-€3.6 billion1, assuming recovery of the WFE market. We also issued new guidance for 2027, including further revenue growth to €4.0-5.0 billion1, as we continue to execute our Growth through Innovation strategy. We also shared that we expect the ALD market to remain among the fastest growing segments with a CAGR of 10%-14% for the period 2022-2027, while in Si Epi we continue to target market share increases. In addition, with SiC Epi we have added a rapidly growing and highly synergistic product line. We are well placed to support our leading logic/foundry customers in the upcoming transition to gate-all-around (GAA), which we expect to increase ASM’s served available market (SAM) by an estimated US$400 million per 100k wafer starts per month.
During the Investor Day we also highlighted actions taken with respect to our commitment to sustainability, such as the recent SBTi verification of our Net Zero 2035 targets, and initiatives to increase the energy efficiency of our products in close collaborations with customers and suppliers.”
On a currency-comparable level, we project revenue of €600-640 million for Q4 2023. Our forecasts for the second half and the full year 2023 are largely unchanged. At constant currencies and taking into account the guidance for Q4, we expect revenue in the second half to drop by approximately 10% compared to the first half of the year, and for FY 2023, we expect revenue to show a year-on-year increase of close to 10%, including the consolidation of LPE.
On October 17, 2023, the US issued new export control measures. Based on our preliminary assessment, we do not expect any material additional impact, relative to what we previously communicated.
Wafer fab equipment (WFE) is now expected to drop by a high single-digit to low double-digit percentage in 2023. Memory WFE is still expected to show the sharpest drop. Compared to memory, leading-edge logic/foundry is relatively resilient but also impacted by the weaker market conditions. The mature node markets are expected to be up this year, although, as mentioned, power/analog is showing signs of slowdown. We continue to expect to outperform the WFE market this year.
Share buyback program
On September 19, 2023, ASM completed the €100 million share buyback program that was started on April 27, 2023. In total, we repurchased 264,503 shares at an average price of €378.07, under the 2023 program.
ASM Investor Day 2023
On September 26, 2023, ASM held its Investor Day, where ASM’s management provided an update on our business and financials, and discussed how new technology developments will drive expected market expansion, new growth opportunities and initiatives to improve sustainability. Highlights included:
- Revenue target for 2025 increased to €3.0-€3.6 billion2, up from the previous 2021 Investor Day target of €2.8-€3.4 billion. Further growth in revenue to €4.0-€5.0 billion by 2027 (2022-2027 CAGR of 11%-16%).
- Gross margin of 46%-50% and operating margin of 26%-31% reiterated for 2023-2025, and also targeted for 2026-20273, with upward trend in operating margin expected in outer years.
- Annual capex of €100-€180 million (in 2024-2027), to support growth.
- Single-wafer ALD market forecast of $3.1-$3.7 billion by 2025 repeated, up from $2.6 billion in 2022; with further expected growth to $4.2-$5.0 billion by 2027, with a continued leading targeted market share of >55%.
- Si Epi market 2025 forecast increased to $1.9-$2.3 billion, compared to market size of $2.0 billion in 2022, with further growth to $2.3-$2.9 billion in 2027. We continue to target an increase in market share to >30% by 2025.
- SBTi’s verification of ASM’s net-zero 2035 targets.
About ASM International
ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, pandemics, epidemics and other risks indicated in the company's reports and financial statements. The company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Quarterly earnings conference call details
ASM will host the quarterly earnings conference call and webcast on Wednesday, October 25, 2023, at 3:00 p.m. CET.
Conference call participants should pre-register using this link to receive the dial-in numbers, passcode and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast, and replay will be accessible at this link.
Investor and media relations
T: +31 88 100 8500
1 Based on WFE market size assumption of $~100 billion in 2025 and $~120 billion in 2027.
2 Based on WFE market size assumption of $~100 billion in 2025 and $~120 billion in 2027.
3 On a normalized basis, excluding fair value adjustments of purchase price allocations.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t